Toll-like receptor (TLR) signaling is a well-characterized, innate immune cellular defense mechanism used to detect and respond to pathogen-associated molecular patterns (PAMPs). TLR signaling is highly conserved and has evolved to have both extracellular and endosomal receptors that recognize PAMPs from a wide range of microbial pathogens. Recent literature has emerged to show that activation of TLRs not only leads to the upregulation of cellular defense mechanisms, but also results in upregulation of DNA repair genes and increased functional DNA repair. Endosomal TLR agonists result in increased survival and repair after both ionizing and UV radiation, suggesting that the repair pathways for single-and double-strand breaks are affected. This review brings together these and other experimental findings to examine how DNA repair pathways may be linked to TLR signaling. Also discussed are the varied outcomes and related physiological implications that increased DNA repair after injury might have.
INTRODUCTION
Toll-like receptors (TLRs) are a main component of the innate immune system that serves as a first line of defense against a wide range of injurious substances. TLR activation not only initiates an inflammatory response that works to combat pathogens, but also potentially results in tissue damage that must be repaired after the infection is neutralized. Among humans and mice, there are currently 13 known TLRs, some of which localize to the cell membrane and are meant to defend against extracellular pathogens, whereas others are located in the endosome and detect intracellular pathogens. These receptors function by recognizing pathogen-associated molecular patterns (PAMPs) . Each TLR responds to very specific PAMPs and initiates the appropriate cellular response to defend against the pathogen that it has recognized. The elegant and complex TLR signaling pathways have been the subject of many well-written and comprehensive reviews, and hence we will give only a brief overview (Trinchieri and Sher, 2007; Barton and Kagan, 2009; Kawai and Akira, 2011) . Teleologically, it may be of survival value to damaged cells and the surrounding tissue to have a way of repairing damage created by TLR-activating agonists, which is the subject of this review.
All TLRs contain two main signaling domains. The first is an extracellular or endosomal pathogen-sensing domain that consists of leucine-rich repeats in the conformation of a shepherd's crook, and the second is an intracellular Toll/ interleukin-1 receptor (TIR) domain that interacts with signaling and adaptor molecules to relay the message that a pathogen has been sensed. These transmembrane proteins function by either homodimerizing or heterodimerizing to create a functional sensing and signaling complex. TLRs 1/2, 2/6, 4/4, and 5/5 are known to be extracellular sensors as they reside in the plasma membrane of the cell, whereas TLRs 3/3, 7/7, 8/8, and 9/9 are considered intracellular sensors as they reside in the membrane of the endosome. There are also reports of TLRs 2 and 4 localizing to and functioning from the endosome (Dietrich et al., 2010; Shibata et al., 2011) . MyD88 (myeloid differentiation primary response gene (88)) is the necessary adaptor molecule that interacts with the TIR domain of all TLRs, except for TLR3, which utilizes TRIF (TIR-domain-containing adapterinducing interferon-b) as its sole adaptor molecule to lead to downstream signaling. TLR4 can use either MyD88 or TRIF to relay its signal, which is thought to depend on where it is localized (McGettrick and O'Neill, 2010) . The varied location of and large number of possible signals from TLR4 make it the most functionally diverse and widely studied TLR. Using distinct combinations of adaptor and signaling molecules, each TLR elicits a tailored response to the pathogen that it senses. For an extensive overview of TLR ligands, both synthetic and naturally occurring, please refer to the review by Kawai and Akira (2011) . The pathogen-specific response of TLRs involves the release of cytokines tailored for neutralization of the activating pathogen, recruitment of necessary immune components by release of chemokines and upregulation of costimulatory molecules, regulation of cell cycle, and, when appropriate, mediation of inflammation (Loegering and Lennartz, 2011; Prince et al., 2011; Waltz et al., 2011) .
TLRs are not only able to sense PAMPs, but they also respond to damage-associated molecular patterns (DAMPs), which are endogenous signaling components released by cells upon acute damage and/or infection. DAMPs are also sensed by TLRs present on surrounding cells. The notion that TLRs are able to recognize and respond to these DAMPs has become widely recognized and the number of known DAMPs has grown rapidly over the past few years (Piccinini and Midwood, 2010) . These DAMPs are most notably created under conditions of oxidative stress, DNA damage, viral infection, and ischemia/reperfusion (Wheeler et al., 2009; Huang et al., 2011; Marichal et al., 2011; Tang et al., 2011) . Comprising many categories of molecules, the list of TLRactivating DAMPs contains proteins/peptides, fatty acids/ lipoproteins, proteoglycans/glycosaminoglycans, and nucleic acids/nucleic acid-protein complexes. Endogenous DAMPs have now been identified for all of the TLRs, which are the subject of many previous reviews that compile lists of known DAMPs associated with many different environmental and disease conditions (Krysko et al., 2011; Kuipers et al., 2011; Miller et al., 2011; Goh and Midwood, 2012; Nace et al., 2012) .
Among the currently identified DAMPs that are known to signal through TLRs, there are a few that are particularly relevant to this review because they are associated with DNA damage and DNA-damaging conditions (Table 1) . In a mouse model of hepatic ischemia/reperfusion, endogenous histone proteins, which are released during DNA-damaging conditions, are shown to activate TLR9 (Huang et al., 2011) . Another DNA-related DAMP is HMGB-1, a chromatinbinding protein, that is a well-recognized DAMP capable of signaling through TLRs 2, 4, and 9. This DNA-associated molecule is implicated in the pathogenesis of a wide range of diseases including skin cancer, epilepsy, and sepsis (Yu et al., 2006; Maroso et al., 2010; Mittal et al., 2010) . Chromatin and other self-DNA complexed with proteins/peptides, when released from the cell, are involved in the pathogenesis of autoimmune disorders such as systemic lupus erythematosus and Sjogren's syndrome. By serving as antigen for autoantibody production, antibodies complexed with self-nucleic acid can then signal through TLRs 7 and 9 to exacerbate pathogenic inflammation (Rubin et al., 1986; Celhar et al., 2012) . The antimicrobial peptide LL37 has also been shown to complex with free self-nucleic acids and serves as a TLR7 and TLR8 agonist (Lande et al., 2007; Ganguly et al., 2009 ). This aberrant TLR activation has been implicated in the pathogenesis of psoriasis. Interestingly, a recent publication shows that UVB-irradiated keratinocytes release damaged self-noncoding RNAs that serve as potent TLR3 agonists (Bernard et al., 2012) . UVB causes extreme DNA damage that must be repaired; further experiments should be conducted to determine whether the described TLR3 activation possibly leads to increased DNA repair. Simple mislocalization and/or aberrant release of these ubiquitously present DAMP molecules can stimulate potentially harmful inflammation through recognition by TLRs and other pattern recognition receptors. The ability of the cell to differentiate a genuine danger signal from a normally functioning molecule speaks of how tightly regulated the TLR signaling process is. This review will focus on how activation of TLR pathways might stimulate increased DNA repair. The aforementioned DAMPs serve as intriguing venues to investigate whether DAMPs arising from DNA-damaging conditions may be helping in initiating repair by signaling through TLRs.
With all of the opportunities present for these TLR signaling pathways to go awry, it is not surprising that they are implicated in the pathogenesis of many diseases and are a target for therapeutics seeking to control the immune response stimulated by TLR agonists. TLR antagonist therapies are routinely used and continue to be under development for treatment of a wide range of diseases including viral infection, lymphoma, melanoma, systemic lupus erythematosus, and rheumatoid arthritis (Sun et al., 2007; Alexandrescu et al., 2010; Ubol and Halstead, 2010; Bourquin et al., 2011) . These drugs target many different parts of the signaling pathway, including controlling TLR signaling by competitive inhibition of the ligand binding site and suppression of homodimerization of the receptors (Park and Youn, 2010; Lee et al., 2011) . Understanding the many complicated and varied mechanisms of regulation and outcomes from the TLR signaling pathways will allow for more specific and appropriate immune modulation therapy for diseased tissue. 
TLR SIGNALING LEADS TO INCREASED DNA REPAIR
Recently, a body of evidence has emerged that shows the upregulation of DNA repair genes and functional DNA repair after treatment with TLR agonists. This is initially surprising because TLR signaling is traditionally thought to defend against exogenous pathogens by mobilizing an inflammatory response and by interfacing with adaptive immunity, rather than leading to increased repair of self-DNA, although, with our growing knowledge of how TLRs respond to DAMPs, perhaps increased repair is a logical downstream effect. Synthetic versions of CpG DNA are the most widely studied TLR9 ligands because of their clinical relevance and therapeutic use. In 2008, Zheng et al. (2008) , while investigating the outcomes of TLR9 engagement on girradiated CD4 þ T cells as it relates to cancer therapeutics, observed that CpG DNA-stimulated CD4 þ T cells exhibited increased DNA repair rates after irradiation. They also showed an increase in the number of cells in the G2 cellcycle phase and a decrease in apoptotic cells as measured by Annexin V staining. This accumulation of cells in the G2 phase of the cell cycle may allow for the increase that is seen in functional double-strand break (DSB) repair, which ultimately leads to increased survival and a decrease in programmed cell death. More recently, a global gene expression analysis was conducted to investigate which families of genes are upregulated and downregulated in vivo upon TLR9 stimulation (Klaschik et al., 2010) . This study finds that, along with several other gene families, there is a significant increase in mouse splenic mRNAs that code for proteins involved in the regulation of cell cycles and DNA repair 5 days after an intraperitoneal injection of CpG DNA. Although splenomegaly was observed on day 5 of these experiments, the ratios of B cells, T cells, and monocyte/ macrophages were similar to those of untreated control spleens, allowing for useful interpretation of gene regulation results. An in-silico gene expression study, using data sets collected after intraperitoneal injection of CpG DNA as well as intranasal inoculation, found similar results; i.e., in immune cells, genes encoding for DNA repair molecules are upregulated (Sommariva et al., 2011) . The upregulation of these cell cycle and DNA repair genes helps to support and explain previous functional findings, and adds to evidence that stimulation of TLR9 not only leads to a proinflammatory response but also results in repair of DNA damage.
Although TLRs 7 and 8 are expressed at varied levels in different tissues and have been shown to activate dendritic cells in distinct ways, both reside in the membrane of the endosome and are known to recognize single-stranded RNAs (Larange et al., 2009) . The TLR7 and TLR8 agonist, Imiquimod, is commonly used as an immune-modulating topical therapeutic agent to treat dermatologic diseases such as HPV infection, nonmelanoma skin cancer, and actinic keratosis (Edwards et al., 1998; Oster-Schmidt, 2004; Hanke et al., 2010; Swanson et al., 2010) . This intracellular TLR agonist has been found to enhance DNA repair gene expression as well as functional repair of DNA damage mechanisms when tested by topical application on the skin of UV-irradiated mice (Fishelevich et al., 2011) . After in vitro treatment of bone marrow-derived cell lines with Imiquimod, nucleotide excision repair (NER) gene expression is found to be increased along with nuclear localization of the repair molecule, xeroderma pigmentosum, complementation group A (XPA). Paired with in vivo experiments that show increased resolution of cyclobutane pyrimidine dimers in UV-irradiated and Imiquimod-treated mice compared with control-irradiated mice, these findings support a more universal role of TLR stimulation in upregulating functional DNA repair.
Aside from upregulation of traditional DNA repair, the TLR7 agonist 8-mercaptoguanosine, in conjunction with IL-4, has been implicated in an increase in class switch recombination and IgG1 production by B cells (Tsukamoto et al., 2009) . Although it remains unclear whether 8-mercaptoguanosine signaling contributes to the DSB repair function necessary for successful class switch recombination, the TLR7 agonist helps to initiate B-cell differentiation and maturation. This observation adds to the growing evidence that TLR signaling is involved in many more complex processes than those previously understood as immunomodulatory functions. Treatment with intracellular TLR agonists for TLR7 and TLR9 seems to result in increased DNA repair processes by several mechanistic readouts. It is noteworthy that there are no recent reports of the same findings using extracellular TLR agonists. However, it has been shown that pretreatment with Lactobacillus bifidus extract causes an increase in DNA repair after UV irradiation, which may be a result of extracellular TLR stimulation by the bacterial extract (Born and Born, 1987) . Although bifidus is commonly included in antiaging creams for its ability to increase DNA repair, this property of the compound has still not been sufficiently confirmed in peer-reviewed literature (Natarajan et al., 1988) . More research is needed to determine whether this phenomenon of TLR-induced DNA repair is limited to intracellular TLRs or whether this result can also be induced by extracellular TLR agonists.
MECHANISMS BY WHICH TLR SIGNALING MIGHT RESULT IN INCREASED DNA REPAIR
The promoter regions of genes known to be involved in the NER pathway, which repairs single-strand breaks (SSBs), have been investigated and a possible link between DNA repair and TLR signaling has been found. The 5 0 promoter regions of all the NER genes studied (ERCC1, XPA, XPB, XPD, XPF, and XPG) contain at least one putative activator protein-1 (AP-1) binding site (Zhong et al., 2000) . AP-1 is a transcription factor known to be induced by TLR signaling, and the existence of its binding sites in promoter regions of many DNA repair genes suggests evidence of an association between TLR signaling and increased functional DNA repair (Figure 1) . However, the existence of AP-1 binding sites is not necessarily the only mechanism of gene regulation and may not be directly correlated with the observed functional increase in DNA repair. Experimental models deficient in TLR and/or AP-1 need to be utilized to determine the importance of the AP-1 binding site in DNA repair genes and also to investigate whether TLR-deficient mice have impaired DNA repair. The TLR signaling pathway, along with its many other known functions, may represent a mechanism that the cell has evolved to coordinately control all of the genes involved in a necessary response to acute damage. This phenomenon has been observed in lower prokaryotic organisms, for example, Saccharomyces cerevisiae, in which there is a conserved transcription factor-binding sequence in the promoter of at least 11 DNA repair and metabolism genes (Xiao et al., 1993) . The ability of TLRs to sense DAMPs makes them ideal candidates for overarching regulation of the DNA repair process. However, somehow the signal to upregulate repair must be differentiated from, and balanced between, the signal to induce a tissue-destructive inflammatory response. Much research is needed to elucidate which molecules are involved in this repair response after TLR signaling and how it might be regulated.
Another way by which TLR activation may upregulate DNA repair is by initiating the production of cytokines that act on the cell in an autocrine or paracrine manner (Figure 1 ). There are reports that mice with UV-induced DNA damage show increased repair of this damage when exogenous IL-12 or IL-18 is injected into the skin (Schwarz and Schwarz, 2009 ). The skin of treated and control mice show the same amount of DNA damage immediately after UV irradiation, measured by the amount of cyclobutane pyrimidine dimers; however, 24 hours after UV exposure, the cyclobutane pyrimidine dimer level is significantly lower in the skin of cytokine-treated mice versus control. Increased DNA repair is also seen when exogenous IL-23 is added to UV-irradiated mice, which might be expected because of the shared p40 subunit between IL-12 and IL-23 (Majewski et al., 2010) . The presence of IL-12, IL-18, or IL-23 is able to stimulate DNA repair mechanisms that result in increased functional repair, and signaling by many TLRs is known to initiate production of these, among many other, cytokines. Interestingly, it has been found that peripheral blood mononuclear cells from xeroderma pigmentosum (XP) patients have significantly attenuated IFN-g production following polyinosinic-polycytidylic acid, a TLR3 agonist, stimulation (Gaspari et al., 1993) . These data can be interpreted as suggesting impaired TLR3 signaling in XP patients. This raises the intriguing possibility that impaired TLR signaling may in some way contribute to the profound DNA repair defects observed in these patients. It is noteworthy that the TLR3 signaling pathway uses TRIF as the sole signaling adaptor molecule; these data may suggest that the TRIF signaling pathway and the MyD88 signaling pathway are involved in the upregulation of DNA repair. Upregulation of DNA repair machinery after autocrine signaling by TLR-induced cytokines may represent a mechanism by which TLR agonist treatment results in increased DNA repair.
UV radiation-induced cellular damage has been implicated in inducing cell signaling pathways that produce proinflammatory cytokines that may signal in the previously described autocrine manner. However, the most commonly observed UV-induced phenotype is one of immune suppression (Muthusamy and Piva, 2010; Norval and Halliday, 2011) . One of the critical hallmarks of the UV effect that results in cutaneous immunosuppression is the migration of antigen-presenting cells impaired by DNA damage to the local lymph node (Vink et al., 1996) . Using a mouse contact www.jidonline.org 299 hypersensitization model, treatment with Imiquimod has been shown to decrease UV-induced immunosuppression (Thatcher et al., 2006) . UV-irradiated animals that are treated with the topical TLR7 agonist, Imiquimod, have less DNA damage in the local draining lymph node when compared with control-irradiated mice. Increased repair that leads to successful antigen presentation may be a mechanism whereby this TLR7 agonist is able to counteract UV immunosuppression.
CATEGORIES OF DNA DAMAGE AND ASSOCIATED MODULATION BY TLR AGONISTS
DNA damage can occur through many routes, including UV radiation, ionizing radiation, chemical agents, oxidative stress, and defective receptor editing (Rastogi et al., 2010; Azzam et al., 2011; Aziz et al., 2012; Dizdaroglu, 2012) . These injurious circumstances result in several types of damage that lead to varied phenotypic outcomes in the cell ( Table 2) . As discussed before, it has become evident that repair of this range of DNA damage may be increased upon activation of TLR signaling. UV and ionizing radiation (g-irradiation) most classically result in SSB and DSB, respectively. Cyclobutane pyrimidine dimers are another main damage associated mainly with UVB irradiation (290-320 nm). These dimers require the NER complex to be excised and corrected, and once this process takes place the integrity of the affected DNA is maintained. Because g-irradiation results in DSB that cannot be repaired using a complementary template, it is associated with mutagenesis and chromosome abnormalities that often lead to cell death. Repair of both UV-and g-irradiation has been shown to be increased after treatment with endosomal TLR agonists (Zheng et al., 2008; Fishelevich et al., 2011) , implying that both the NER and DSB repair complexes are stimulated. Pathogens, although not classically known to directly cause host DNA damage, can initiate an inflammatory immune response through TLR signaling that leads to an environment with increased oxidative stress. This oxidative stress and associated reactive oxygen species are a prominent cause of DNA damage, most notably SSB and instability of histones due to methylation inhibition (Evans and Cooke, 2004) . These conditions are well known to lead to the release of DAMPs that signal through TLRs on self and surrounding cells. The reactive oxygen species-induced DAMP signaling classically leads to inflammation and associated tissue damage; however, conditions of oxidative stress also lead to the eventual repair of affected tissue (Gill et al., 2010) . It is possible that when a PAMP is sensed by a TLR, DNA-damaging reactive oxygen species are released, which are then followed by the release of DAMPs that signal through TLRs to help promote repair; however, much research is needed to confirm this hypothesis.
OUTCOMES OF INCREASED DNA REPAIR
After unintentional damage by exposure to a genotoxic agent, increased repair can be a positive outcome for a cell that has an important putative role in host defense, for example, an antigen-presenting cell. However, increased repair in cells that have been programmed for death, that are infected with a pathogen, or that are being deliberately targeted for death using a chemotherapeutic drug may result in an undesirable outcome. For example, if a severely UV-damaged skin cell repairs itself enough to surpass the DNA damage checkpoint during cell cycle, growth will not be arrested and the cell may divide, allowing for propagation of a mutation that could render the cell cancerous. In this scenario, it might be advantageous to inhibit TLR signaling so that repair will not be increased, damage can be recognized, and the cell deleted. Lewis et al. (2011) found that TLR4 signaling contributes to UV immune suppression by promoting T regulatory cell formation. Therefore, they proposed that TLR inhibition therapy may prevent dampening of a necessary immune response. They did not investigate how UV irradiation activated TLR4 signaling, or how the induction of DAMPs may be involved. The study also did not resolve, on a molecular level, how TLR4 enhanced immune suppression. Nonetheless, this intriguing finding suggests that TLR and the PAMPs/DAMPs that engage them could present opposing signals in the setting of genotoxic challenges. Further research is needed to clarify these apparently divergent outcomes of TLR signaling. Cancer chemotherapy is another example of a situation where increased DNA repair is not a favorable outcome. Such therapy may use DNA-damaging chemotherapeutic agents targeted to tumor cells to cause cell death. In this scenario, if repair is increased, the undesirable outcome of increased survival of tumor cells would be expected. However, just the opposite has been observed. TLR agonists have been shown to work synergistically with the chemotherapeutic drug cyclophosphamide (a known genotoxic agent) (Dumitru et al., 2010) . By mechanisms not yet elucidated, the TLR agonist sensitizes the tumor cells to DNA damage, which, given the previously discussed findings, is not what would be expected. The same phenomenon is seen in the work by Sommariva et al. (2011) , in which TLR9 agonist treatment caused the upregulation of DNA repair genes in immune cells but exactly the opposite in tumor cells, which aided in their death. Upregulation or downregulation of DNA repair may represent a molecular biological explanation for the synergy seen when chemotherapy is administered with TLR agonists (Larange et al., 2009) . These studies suggest that the tumor microenvironment evolves into an area that is advantageous for treatment with agents that stimulate TLR signaling. In this environment, DNA repair in nondiseased cells might be increased, and in tumor cells DNA repair might be decreased. These phenomena need further investigation in order to understand better how immune versus stromal cells, or normal versus cancerous cells, respond to TLR agonists and associated DNA repair/cell survival.
DISCUSSION
The paradoxical data discussed in this review imply that TLR signaling in some environments can lead to increased DNA repair, whereas in others the opposite might be true. However, overall, the evidence presented suggests that the TLR signaling pathways and cell fate might be connected through the DNA repair pathway. Supporting this hypothesis, a recent study found that TLR expression is regulated by DNA metabolic stress and the p53 pathway (Menendez et al., 2011) . Pathogens are well known to signal through TLRs and cause the subsequent upregulation of TLR expression; the fact that genotoxic stress and DNA damage might have the same effect on the TLR pathways is consistent with the data discussed in this review. If the molecular signaling pathway of a TLR that leads to promotion or inhibition of DNA repair, or vice versa, and the conditions necessary for each outcome can be elucidated, then TLR modulation could represent a breakthrough in how to control cell fate, either death or survival, where appropriate. Because multiple drugs involved in TLR modulation are already approved for use, elucidation of this pathway and how it might be related to a wide range of diseases present a unique opportunity for rapid treatment and observation of a successful clinical outcome.
More work is needed to determine whether all TLRs are involved in augmenting DNA repair. TLR and their numerous agonists (PAMPs and DAMPs) present fine-tuned, tailored signals at the cellular level, which have profound effects on shaping the type of immune response that is elicited. Many more experiments are necessary to investigate whether, in the case of TLR and DNA repair, the same types of diversity may be present, resulting in enhanced or decreased DNA repair, control of cell survival or death, emergence or deletion of cancer cells, and immune competence or immune suppression. Figuring out how DNA repair may be involved in resolving this cell-fate paradox presents an exciting opportunity to better understand a novel attribute of TLR signaling.
